

Myomo, Inc. (MYO)

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001369290

Myomo, Inc.

MYO; healthcare

Grade

B/C

A

B

C

D

E

on the B/C boundary of 371 graded peers

percentile 40.8; sampling error 2.5 points; lower is stronger

Rank

152 of 371

Profitability

C

percentile 47.5

Solvency

D

percentile 63.0

Growth and financing

B

percentile 26.0

Reliability

0.83 AUC

filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025

Peer failure rate

1.07% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$12.5M to \$120M assets

total assets \$38.6M

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

none active; fortress balance sheet

Inputs computable

9 of 14

Graded from

filings received through Apr 29, 2026

163 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026

Last close

\$1.40

2026-10-08; market equity \$55.5M

Price used in grade

None



B/C, the elk

on the B/C boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from Mar 21, 2025, B/C from Jun 21, 2026, C from Aug 21, 2026, B/C from Sep

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.5						
Gross profitability		69.6%	32.2%	11.9	372	2025-12-31
Return on invested capital		not computable	9.3%			a prior annual debt, equity, and cash observation is required
Accruals ratio		(2.6%)	(6.6%)	73.3	811	2025-12-31
Gross margin stability, five years		3.3 pts	2.8 pts	57.4	243	2025-12-31
Solvency, sleeve percentile 63.0						
Twelve-month failure probability		0.28%	0.07%	75.7	248	2026-06-30
Altman Z double-prime		(8.82)	(0.31)	59.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.30x	2.96x	53.9	839	2025-12-31
Growth and financing, sleeve percentile 26.0						
Revenue growth, three-year compound		38.1%	10.0%	17.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		56.1%	2.1%	6.7	704	2025-12-31
Net share issuance, one year		12.0%	2.5%	53.6	634	2026-03-02


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,909,872 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
147	Biolife Solutions Inc. (BLFS)	39.5	B/C	fortress balance sheet
148	Celldex Therapeutics, Inc. (CLDX)	39.7	B/C	short runway
149	National Healthcare Corp. (NHC)	40.0	B/C	fortress balance sheet
150	ImmunityBio, Inc. (IBRX)	40.3	B/C	short runway
151	Shattuck Labs, Inc. (STTK)	40.5	B/C	dilution
152	Myomo, Inc. (MYO) <	40.8	B/C	fortress balance sheet
153	Lifevantage Corp. (LFVN)	41.1	B/C	
154	Repligen Corp. (RGEN)	41.4	B/C	late filer, fortress balance sheet
155	Envista Holdings Corp. (NVST)	41.6	B/C	
156	Xeris Biopharma Holdings, Inc. (XERS)	41.9	B/C	
157	Sight Sciences, Inc. (SGHT)	42.2	B/C	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	67.0%	8.0%	82
Distance from 52-week high	(24.2%)	(31.4%)	59
EBIT to enterprise value	(25.6%)	(1.5%)	21
Free cash flow yield	(29.1%)	(1.0%)	19
Book value to price	0.10	0.28	26
Sales to price	0.73	0.31	77
Composite equity issuance, five years	195.9%	20.3%	89
Relative strength against the sector, log excess return	0.30	(0.14)	82

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	

Cash and equivalents	\$11.2M
Operating cash flow, four quarters	-\$7.1M
Months of runway	18.9
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$497,334

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$26.9M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
2	assets	us-gaap:Assets	\$38.6M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
3	operating income	us-gaap:OperatingIncomeLoss	-\$14.4M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$15.1M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$504,532	2025-12-31	2026-03-09	10-K	0001193125-26-098531
6	total debt	us-gaap:LongTermDebt	\$11.2M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
7	book equity	us-gaap:StockholdersEquity	\$11.4M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$14.1M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
9	net income	us-gaap:NetIncomeLoss	-\$15.6M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.5M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
11	assets	us-gaap:Assets	\$42.2M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$40.9M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
13	gross profit	us-gaap:GrossProfit	\$23.2M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$32.6M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
15	gross profit	us-gaap:GrossProfit	\$13.2M	2023-12-31	2025-03-10	10-K	0000950170-25-036349
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$19.2M	2023-12-31	2025-03-10	10-K	0000950170-25-036349
17	gross profit	us-gaap:GrossProfit	\$10.3M	2022-12-31	2024-03-08	10-K	0000950170-24-028326
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.6M	2022-12-31	2024-03-08	10-K	0000950170-24-028326
19	gross profit	us-gaap:GrossProfit	\$10.3M	2021-12-31	2023-03-13	10-K	0000950170-23-007560
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.9M	2021-12-31	2023-03-13	10-K	0000950170-23-007560
21	current assets	us-gaap:AssetsCurrent	\$27.6M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
22	current liabilities	us-gaap:LiabilitiesCurrent	\$8.3M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$118.7M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
24	liabilities	us-gaap:Liabilities	\$27.2M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
25	depreciation amortization	us-gaap:Depreciation	\$859,354	2025-12-31	2026-03-09	10-K	0001193125-26-098531
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.7M	2025-12-31	2026-03-09	10-K	0001193125-26-098531
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.3M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.4M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.2M	2023-12-31	2025-03-10	10-K	0000950170-25-036349
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$145,816	2023-12-31	2025-03-10	10-K	0000950170-25-036349
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$10.2M	2022-12-31	2024-03-08	10-K	0000950170-24-028326
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$111,793	2022-12-31	2024-03-08	10-K	0000950170-24-028326
33	current assets	us-gaap:AssetsCurrent	\$32.8M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
34	current liabilities	us-gaap:LiabilitiesCurrent	\$10.2M	2024-12-31	2026-03-09	10-K	0001193125-26-098531
35	assets	us-gaap:Assets	\$14.6M	2023-12-31	2025-03-10	10-K	0000950170-25-036349
36	assets	us-gaap:Assets	\$10.2M	2022-12-31	2024-03-08	10-K	0000950170-24-028326
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,511,715	2026-03-02	2026-04-29	10-K/A	0001193125-26-191496
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	34,381,125	2025-03-01	2025-03-10	10-K	0000950170-25-036349